Skip to content
OABI·Nasdaq·US

OmniAb

OmniAb licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its platform creates and screens diverse antibody repertoires using proprietary engineered transgenic animals to identify antibodies and other target-binding proteins for partners' drug development. As of December 31, 2025, it had 107 active partners with 407 active programs.

Source: SEC 10-K Mar 4, 2026

Thematic Position

OABI

Relationship Groups

Competitors6

Relationship details are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

AI regulationcompliance requirementsfines
EU AI Act and Product Liability Directive impose compliance requirements on OmniAb's AI Technologies use
SEC 10-KMar 4, 2026

The full regulatory passage is part of the Pro plan.

1 more · Regulatory and geopolitical insights are part of the Pro plan.